Icecure Medical (TASE:ICCM), (NASDAQ:ICCM) specializes in developing and marketing minimally invasive cryoablation therapies for treating tumors. This innovative approach allows for the destruction of tumors by freezing without the need for traditional surgical removal. Icecure Medical's flagship project, ProSense, is a state-of-the-art system designed to provide a nonsurgical alternative for patients with tumors in various organs, including the breast, kidney, bone, and lungs. The company's objective is to transform cancer treatment by offering safer, cost-effective, and less invasive solutions compared to conventional surgeries, expanding the possibilities for cancer care worldwide. Icecure Medical aims to continue advancing its technology and increase its market presence, demonstrating a commitment to improving patient outcomes and quality of life.